Regular ArticleA Phase II Trial of Daily Perillyl Alcohol in Patients with Advanced Ovarian Cancer: Eastern Cooperative Oncology Group Study E2E96☆
References (13)
- et al.
Hexamethylmelamine as second-line therapy for platin-resistant ovarian cancer
Gynecol Oncol
(1992) - et al.
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study
J Clin Oncol
(1996) - et al.
Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study
J Clin Oncol
(1994) New developments in the treatment of ovarian cancer
Exp Opin Investig Drugs
(2001)- et al.
The anticancer monoterpene perillyl alcohol causes a decrease in cellular cyclin D1 levels contributing to an early G1 arrest in mammary cells
Proc Annu Meet Am Assoc Cancer Res
(1997) - et al.
Selective inhibition of isoprenylation of 21–26 kDa proteins by the anticarcinogen d-limonene and its metabolites
J Biol Chem
(1994)
Cited by (69)
Perillyl alcohol as a treatment for cancer: A systematic review
2021, Phytomedicine PlusCitation Excerpt :A study that evaluated objective response according to the Response Evaluation Criteria in Solid Tumours (RECIST) in women with ovarian cancer treated with platinum-based chemotherapy reported results considerably superior to those found in treatment with POH, with a CR of 4% and a PR of 58% (Morgan et al., 2021). Another study on the effectiveness of treatment with chemotherapy (treosulfan and leuprorelin) in ovarian cancer, which, like the POH trials, did not achieve any ORR, reported an SD with a minimum duration of 4 weeks in 17.8% of patients, and an average progression-free survival (PFS) of 13.5 weeks (Bois et al., 2002), while one study with POH reported SD with an average of 17.1 weeks in 100% of ovarian cancer patients, and another SD of 25.7 weeks in 17% of ovarian cancer patients with an average PFS of 7.2 weeks (Bailey et al., 2002; Ripple et al., 1998). Such results reveal a superior objective response in standard treatments, and, although there is a tendency of superiority of POH in relation to the cytostatic effect, evidenced by the results achieved in respect of SD, the significance of this result should not be over-estimated due to the lower mean PFS obtained in respect of the POH treatment, and the different sample sizes.
Effect of Different Tensoactives on the Morphology and Release Kinetics of PLA-b-PEG Microcapsules Loaded With the Natural Anticancer Compound Perillyl Alcohol
2019, Journal of Pharmaceutical SciencesMonoterpenes modulating cytokines - A review
2019, Food and Chemical ToxicologyCitation Excerpt :PA has also been tested for prostate cancer in phase-II clinical trials(Liu et al., 2003). and for colon and ovarian cancer (Bailey et al., 2002; Meadows et al., 2002). This monoterpene has neuroprotective effects, which may be applicable in the preventive treatment of stroke (Imamura et al., 2014).
Perillyl alcohol suppresses antigen-induced immune responses in the lung
2014, Biochemical and Biophysical Research CommunicationsIntranasal Delivery of Perillyl Alcohol (NEO100) as a New Treatment Strategy for Glioma
2024, Drug Delivery Letters
- ☆
This study was coordinated by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D.) and supported by Public Health Service Grants CA23318, CA66636, CA21115, CA21076, and CA14958 and grants from the National Cancer Institute, National Institutes of Health, and Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.
- 2
To whom correspondence should be addressed. University of Wisconsin—Madison, K4/3 CSC 600 Highland Avenue, Madison, WI 53792. Fax: (608) 263-8613. E-mail: [email protected].